About: Spesolimab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody medication used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL1RL2/IL1RAP) antibody. It was approved for medical use in the United States in September 2022.

Property	Value
dbo:abstract	Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody medication used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL1RL2/IL1RAP) antibody. It was approved for medical use in the United States in September 2022. (en)
dbo:alternativeName	Spevigo (en)
dbo:casNumber	2097104-58-8
dbo:drugbank	DB15626
dbo:fdaUniiCode	5IB2J79MCX
dbo:kegg	D12066
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/spesolimab
dbo:wikiPageID	71664280 (xsd:integer)
dbo:wikiPageLength	6571 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1118475541 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Generalized_pustular_psoriasis dbr:Monoclonal_antibody dbr:Committee_for_Medicinal_Products_for_Human_Use dbc:Orphan_drugs dbr:European_Medicines_Agency dbc:Breakthrough_therapy dbc:Monoclonal_antibodies dbr:IL1RL2 dbr:IL1RAP dbr:Intravenous_infusion
dbp:atcPrefix	L04 (en)
dbp:atcSuffix	AC22 (en)
dbp:c	6480 (xsd:integer)
dbp:casNumber	2097104 (xsd:integer)
dbp:dailymedid	Spesolimab (en)
dbp:drugbank	DB15626 (en)
dbp:h	9988 (xsd:integer)
dbp:kegg	D12066 (en)
dbp:legalUs	Rx-only (en)
dbp:mabType	mab (en)
dbp:n	1736 (xsd:integer)
dbp:o	2012 (xsd:integer)
dbp:routesOfAdministration	dbr:Intravenous_infusion
dbp:s	46 (xsd:integer)
dbp:source	zu (en)
dbp:synonyms	BI-655130, spesolimab-sbzo (en)
dbp:target	Interleukin 36 receptor (en)
dbp:tradename	Spevigo (en)
dbp:type	mab (en)
dbp:unii	5 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Cite_web dbt:Infobox_drug dbt:Pharma-stub dbt:Portal_bar dbt:Reflist dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:Monoclonals_for_immune_system dbt:Immunosuppressants
dcterms:subject	dbc:Orphan_drugs dbc:Breakthrough_therapy dbc:Monoclonal_antibodies
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody medication used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL1RL2/IL1RAP) antibody. It was approved for medical use in the United States in September 2022. (en)
rdfs:label	Spesolimab (en)
owl:sameAs	wikidata:Spesolimab https://global.dbpedia.org/id/Giirc
prov:wasDerivedFrom	wikipedia-en:Spesolimab?oldid=1118475541&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Spesolimab
is dbo:wikiPageRedirects of	dbr:Spesolimab-sbzo dbr:Spevigo
is dbo:wikiPageWikiLink of	dbr:ATC_code_L04 dbr:List_of_therapeutic_monoclonal_antibodies dbr:Spesolimab-sbzo dbr:Spevigo
is foaf:primaryTopic of	wikipedia-en:Spesolimab